Calle José Isbert, 2
Pozuelo de Alarcón
Madrid 28223
Spain
34 91 021 30 00
https://www.rovi.es
Settore/i:
Settore:
Impiegati a tempo pieno: 1.925
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Ivan Lopez-Belmonte Encina | Second Deputy Chairman & GM of Commercial and Development | 472k | N/D | N/D |
Mr. Javier Lopez-Belmonte Encina | First Deputy Chairman, GM of Industrial Operations & CFO | 474k | N/D | N/D |
Mr. Juan Lopez-Belmonte Encina | Chairman & CEO | 1,15M | N/D | N/D |
Marta Campos Martínez | Head of Investor Relations | N/D | N/D | N/D |
Ms. Mercedes Benítez del Castillo Sánchez | Legal Department Manager | N/D | N/D | N/D |
Ms. Beatriz Ávila Alcalde | Sales Manager | N/D | N/D | N/D |
Ms. Rosario Perucha Pérez | Marketing Manager | N/D | N/D | N/D |
Mr. Francisco Javier Angulo García | Human Resources Manager | N/D | N/D | N/D |
Mr. Gabriel Nunez Fernandez | Secretary | N/D | N/D | N/D |
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
L'ISS Governance QualityScore di Laboratorios Farmaceuticos Rovi, S.A. al 1 aprile 2024 è 4. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 7; diritti degli azionisti: 6; retribuzione: 1.